Idarubicin (HCl)

Idarubicin (HCl) is antineoplastic agent or anticancer drug. Idarubicin (HCl) is a synthetic analog of anthracycline daunorubicin. Idarubicin differ from daunorubicin by the absence of methoxy group at the C-4 position. Idarubicin (HCl) is effective in the treatment of different types of cancers. Idarubicin (HCl) is used in combination of other anticancer drugs to obtain best therapeutic effects and to reduce toxicity or side effects. It has less potentially less cardiotoxicity than doxorubicin and daunorubicin. Idarubicin (HCl) is administered orally or intravenously.

Idarubicin (HCl) is primarily indicated in conditions like Acute erythroleukemia, Acute myelogenous leukemia, Acute non-lymphoblastic leukemia, Acute non-lymphocytic leukemia, Acute promyelocytic leukemia, Advanced breast or prostate cancer, and can also be given in adjunctive therapy as an alternative drug of choice in Breast cancer, Multiple myeloma, Non-Hodgkin's lymphoma.

Idarubicin (HCl) is contraindicated in conditions like Bone marrow suppression.

The severe or irreversible adverse effects of Idarubicin (HCl), which give rise to further complications include Urticaria, Neutropenia, Seizures, Cardiomyopathy, Pancytopenia, Leukopenia. Idarubicin (HCl) produces potentially life-threatening effects which include Congestive heart failure, Myelosuppression, Fatal arrhythmias. which are responsible for the discontinuation of Idarubicin (HCl) therapy. The signs and symptoms that are produced after the acute overdosage of Idarubicin (HCl) include Arrhythmias. The symptomatic adverse reactions produced by Idarubicin (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Alopecia, Diarrhea, Mucositis, Abdominal pain, Cardiac arrhythmias, Stomatitis, Anemia, Discoloration of urine, Sinus tachycardia, Supraventricular tachycardia, Bullous rash.

Idarubicin is not recommended for use during pregnancy or lactation. It should be used with caution in patients with any pre-existing liver disease, kidney disease, heart disease, blood disorders or any allergy. Therapy should not be initiated until patient recover normal hematopoiesis after bone merrow depression. It should be used with caution in patient with dental diseases. IM injection should not be administered to the patients receiving idarubicin.

Drug should not be given to Pediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

12 mg/m sq. (22 (22)) 24 hourly Slow IV — Over 10-15 minutes.

45 mg/m2 (45 (45)) As recommended. For 3 days. —

No neonatal dosage information is recorded for this medicine yet.

Idarubicin (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementIchthammolThere are no documented incompatibilities with Idarubicin (HCl),Idarubicin (HCl) usefull iteraction in combination with us trarabine as part of a combinatination chemotherapy for leukemia. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Inj (reconstituted soln) Store at room temperature or refrigerator. Protect from Sunlight. Use within 1 week if refrigerated and within 72 hrs if kept at room temperature.